
Roman Shapiro
@roma_shap
Instructor at Harvard Medical School/Dana-Farber Cancer Institute, with an academic focus on NK cell therapy and management of post transplant relapse
ID: 2263611721
https://plus.google.com/u/0/b/112119322230693038143/112119322230693038143/posts 27-12-2013 01:54:23
25 Tweet
104 Followers
66 Following


Giving an overview of our robust translational NK cell program at Farber. Three trials in advanced stages (one open) plus two in the pipeline and several exciting projects in the lab... loving our highly collab research environment Dana-Farber Harvard Medical School




This pending #vincristineshortage is truly scary given how fundamental this drug (FDA approved 1963!) is in treatment of cancer. Not only a bedrock of treatment for childhood leukemia, it is part of the most common regimens for non-Hodgkin lymphoma (R-CHOP) & adult ALL. The Leukemia & Lymphoma Society


Chronic Myelomonocytic Leukemia: 2020 Update on Diagnosis, Risk Stratification and Management onlinelibrary.wiley.com/doi/abs/10.100… Latest on genetics, epigenetics, ARCH,O-CMML & personalized therapies Mayo Clinic Comprehensive Cancer Center Guillermo Sanz G Garcia-Manero David Steensma, MD Sanam Loghavi, MD صنم لغوی 🔬🧬 Julie Feldstein,MD Naseema Gangat




We are excited to share our new story Nature Immunology on how an adaptation of MDS HSPCs to inflammation contributes to a competitive advantage. Congrats to Tomoya Muto and the awesome team G Garcia-Manero MD Anderson Cancer Center UC San Francisco Cincinnati Children's Leukemia & Lymphoma Society Research. rdcu.be/b3FHz

Proud to be part of such a great team Rizwan Romee Dana-Farber


Wake up Canada! We need to invest on strategic technologies and pharma. It’s vaccine and PPE now next would be IVIG, chemotherapy drugs, CAR-T cell etc...Justin Trudeau theglobeandmail.com/politics/artic…

